These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 8100096)
1. Is L-dopa an endogenous neurotransmitter? Misu Y; Goshima Y Trends Pharmacol Sci; 1993 Apr; 14(4):119-23. PubMed ID: 8100096 [TBL] [Abstract][Full Text] [Related]
2. Is DOPA a neurotransmitter? Misu Y; Goshima Y; Miyamae T Trends Pharmacol Sci; 2002 Jun; 23(6):262-8. PubMed ID: 12084631 [TBL] [Abstract][Full Text] [Related]
3. L-3,4-Dihydroxyphenylalanine as a neurotransmitter candidate in the central nervous system. Misu Y; Kitahama K; Goshima Y Pharmacol Ther; 2003 Feb; 97(2):117-37. PubMed ID: 12559386 [TBL] [Abstract][Full Text] [Related]
4. L-dihydroxyphenylalanine and its decarboxylase: new ideas on their neuroregulatory roles. Opacka-Juffry J; Brooks DJ Mov Disord; 1995 May; 10(3):241-9. PubMed ID: 7651438 [TBL] [Abstract][Full Text] [Related]
5. Baroreceptor-aortic nerve-mediated release of endogenous L-3,4-dihydroxyphenylalanine and its tonic depressor function in the nucleus tractus solitarii of rats. Yue JL; Okamura H; Goshima Y; Nakamura S; Geffard M; Misu Y Neuroscience; 1994 Sep; 62(1):145-61. PubMed ID: 7816196 [TBL] [Abstract][Full Text] [Related]
6. l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease. Goshima Y; Masukawa D; Kasahara Y; Hashimoto T; Aladeokin AC Front Pharmacol; 2019; 10():1119. PubMed ID: 31632270 [TBL] [Abstract][Full Text] [Related]
7. Altered tonic L-3,4-dihydroxyphenylalanine systems in the nucleus tractus solitarii and the rostral ventrolateral medulla of spontaneously hypertensive rats. Yue JL; Okumura Y; Miyamae T; Ueda H; Misu Y Neuroscience; 1995 Jul; 67(1):95-106. PubMed ID: 7477914 [TBL] [Abstract][Full Text] [Related]
8. Autoradiographic studies using L-[(14)C]DOPA and L-DOPA reveal regional Na(+)-dependent uptake of the neurotransmitter candidate L-DOPA in the CNS. Sugaya Y; Sasaki Y; Goshima Y; Kitahama K; Kusakabe T; Miyamae T; Kato T; Misu Y Neuroscience; 2001; 104(1):1-14. PubMed ID: 11311526 [TBL] [Abstract][Full Text] [Related]
9. Review on the relationship between nicotinic acetylcholine receptors and dopaminergic neurotransmission in the central nervous system--dopa is an endogenous neuroactive substance. Misu Y; Nakamura S; Goshima Y; Yue JL; Miyamae T; Kubo T Yakubutsu Seishin Kodo; 1993 Jun; 13(3):199-210. PubMed ID: 8237136 [TBL] [Abstract][Full Text] [Related]
10. Aromatic L-amino acid decarboxylase immunoreactive cells in the rat striatum: a possible site for the conversion of exogenous L-DOPA to dopamine. Mura A; Jackson D; Manley MS; Young SJ; Groves PM Brain Res; 1995 Dec; 704(1):51-60. PubMed ID: 8750961 [TBL] [Abstract][Full Text] [Related]
11. The central aromatic amino acid DOPA decarboxylase inhibitor, NSD-1015, does not inhibit L-DOPA-induced circling in unilateral 6-OHDA-lesioned-rats. Treseder SA; Rose S; Jenner P Eur J Neurosci; 2001 Jan; 13(1):162-70. PubMed ID: 11135014 [TBL] [Abstract][Full Text] [Related]
12. DopAmide: Novel, Water-Soluble, Slow-Release l-dihydroxyphenylalanine (l-DOPA) Precursor Moderates l-DOPA Conversion to Dopamine and Generates a Sustained Level of Dopamine at Dopaminergic Neurons. Atlas D CNS Neurosci Ther; 2016 Jun; 22(6):461-7. PubMed ID: 26861609 [TBL] [Abstract][Full Text] [Related]
13. Dual effects of L-3,4-dihydroxyphenylalanine on aromatic L-amino acid decarboxylase, dopamine release and motor stimulation in the reserpine-treated rat: evidence that behaviour is dopamine independent. Fisher A; Biggs CS; Eradiri O; Starr MS Neuroscience; 2000; 95(1):97-111. PubMed ID: 10619466 [TBL] [Abstract][Full Text] [Related]
14. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites. Alachkar A; Brotchie JM; Jones OT Neurosci Res; 2010 Sep; 68(1):44-50. PubMed ID: 20542064 [TBL] [Abstract][Full Text] [Related]
15. In vivo antagonism of the behavioral responses to L-3-,4-dihydroxyphenylalanine by L-3-,4-dihydroxyphenylalanine cyclohexyl ester in conscious rats. Matsushita N; Misu Y; Goshima Y Eur J Pharmacol; 2009 Mar; 605(1-3):109-13. PubMed ID: 19168057 [TBL] [Abstract][Full Text] [Related]
16. Endogenously released DOPA is a causal factor for glutamate release and resultant delayed neuronal cell death by transient ischemia in rat striata. Furukawa N; Arai N; Goshima Y; Miyamae T; Ohshima E; Suzuki F; Fujita K; Misu Y J Neurochem; 2001 Feb; 76(3):815-24. PubMed ID: 11158253 [TBL] [Abstract][Full Text] [Related]
17. The neuroregulatory properties of L-DOPA. A review of the evidence and potential role in the treatment of Parkinson's disease. Tedroff JM Rev Neurosci; 1997; 8(3-4):195-204. PubMed ID: 9548232 [TBL] [Abstract][Full Text] [Related]
18. Protective effects of L-dopa and carbidopa combined treatments on human catecholaminergic cells. Colamartino M; Padua L; Meneghini C; Leone S; Cornetta T; Testa A; Cozzi R DNA Cell Biol; 2012 Nov; 31(11):1572-9. PubMed ID: 23020119 [TBL] [Abstract][Full Text] [Related]
19. The localization and functional contribution of striatal aromatic L-amino acid decarboxylase to L-3,4-dihydroxyphenylalanine decarboxylation in rodent parkinsonian models. Nakamura K; Ahmed M; Barr E; Leiden JM; Kang UJ Cell Transplant; 2000; 9(5):567-76. PubMed ID: 11144954 [TBL] [Abstract][Full Text] [Related]
20. [Transmitter-like release and pharmacological activities of levodopa]. Goshima Y Nihon Yakurigaku Zasshi; 1993 Jul; 102(1):11-21. PubMed ID: 8101507 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]